Delving into the Latest Updates on Meningococcal A/C vaccine(Hualan Biological Bacterin Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Polysaccharide vaccine, Prophylactic vaccine

Synonyms

A群C群脑膜炎球菌多糖疫苗, Group A and C Meningococcal Polysaccharide Vaccine

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesNervous System Diseases

Active Indication

EncephalomyelitisMeningitis

Inactive Indication

Meningococcal Infections

Originator Organization

Hualan Biological Vaccine, Inc.

Active Organization

Hualan Biological Vaccine, Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (12 Mar 2018),

Encephalomyelitis

Regulation-

Login to view timeline

Author: Bricks, Lucia Ferro ; Sáfadi, Marco Aurelio Palazzi ; Sato, Helena Keico ; Sacchi, Claudio Tavares ; Gorla, Maria Cecilia Outeiro ; Cassio de Moraes, José ; Fukasawa, Lucila O. ; Gonçalves, Maria Gisele ; Ribeiro, Ana Freitas ; Brandileone, Maria Cristina Cunto ; Higa, Fabio ; Carvalhanas, Telma Regina Marques Pinto ; Paula de Lemos, Ana ; Salgado, Maristela

During 2010, outbreaks of serogroup C meningococcal (MenC) disease occurred in 2 oil refineries in São Paulo State, Brazil, leading to mass vaccination of employees at 1 refinery with a meningococcal polysaccharide A/C vaccine. A cross-sectional study was conducted to assess the prevalence of meningococci carriage among workers at both refineries and to investigate the effect of vaccination on and the risk factors for pharyngeal carriage of meningococci. Among the vaccinated and nonvaccinated workers, rates of overall meningococci carriage (21.4% and 21.6%, respectively) and of MenC carriage (6.3% and 4.9%, respectively) were similar. However, a MenC strain belonging to the sequence type103 complex predominated and was responsible for the increased incidence of meningococcal disease in Brazil. A low education level was associated with higher risk of meningococci carriage. Polysaccharide vaccination did not affect carriage or interrupt transmission of the epidemic strain. These findings will help inform future vaccination strategies.

01 Sep 2007·The Lancet Infectious DiseasesQ1 · MEDICINE

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

Q1 · MEDICINE

Review

Author: Michael Hochman ; Katherine L O'Brien ; David Goldblatt

Streptococcus pneumoniae is a major cause of morbidity and mortality in children less than 5 years of age. Prevention of pneumococcal disease and death in children in the developing world through vaccination with recently developed, highly efficacious pneumococcal conjugate vaccines (PCVs) is now possible. Schedules combining PCV with 23-valent pneumococcal polysaccharide vaccine (PPV23) have been studied and proposed as a means to expand disease protection against serotypes not included in the PCVs. Studies of group A and C meningococcal polysaccharide vaccine and repeated doses of PPV23 in adults and children have shown that a state of immune tolerance, or hyporesponsiveness, can develop to repeated polysaccharide vaccine antigen exposures. In this Review, we describe the evidence for and against this hyporesponsiveness and explore the possible mechanisms for such an occurrence.

01 May 2005·VaccineQ3 · MEDICINE

The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt

Q3 · MEDICINE

Article

Author: Francis Mahoney ; Nadia A. Teleb ; Isabelle Nakhla ; Hoda Mansour ; Said El Oun ; Yehia Sultan ; Robert W. Frenck

BACKGROUNDThe strategy recommended by the World Health Organization (WHO) to curtail outbreaks of meningococcus in Africa is enhanced surveillance with administration of oily chloramphenicol as well as vaccination when incidence thresholds are exceeded. The role of capsular polysaccharide meningococcal vaccine in outbreak prevention has been the subject of considerable debate. The Egyptian Ministry of Health and Population initiated a school-based vaccination program with bivalent A/C capsular polysaccharide vaccine in 1992. This investigation reviews data on meningococcal meningitis in Egypt comparing years before and after introduction of the vaccine.METHODSThis is a retrospective review of several sources to examine the rates and serogroups of meningococcal meningitis before and after the introduction of the meningococcal A/C vaccine in Egypt.FINDINGSBetween 1967 and 1991, outbreaks of meningococcal disease were documented with a periodicity of 8 years in Egypt. However, there has not been an outbreak since 1991 and over the same period, there has also been a progressive decline in the baseline incidence of meningococcus. Also, a shift from a serogroup A to serogroup B predominance in meningococcal disease was noted during the study period. These data suggest that there has been an alteration in the epidemiology of meningococcal disease in Egypt that coincided with the implementation of the school-based vaccination program.INTERPRETATIONRoutine use of the bivalent A/C meningococcal vaccine may be an alternative for the control and prevention of meningococcal disease in high-risk areas including the "meningitis belt".

100 Deals associated with Meningococcal A/C vaccine(Hualan Biological Bacterin Co., Ltd.)

Login to view more data